Pliant Therapeutics Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Bernard Coulie
Chief executive officer
US$11.2m
Total compensation
| CEO salary percentage | 5.5% |
| CEO tenure | 8.8yrs |
| CEO ownership | 1.1% |
| Management average tenure | 8.8yrs |
| Board average tenure | 7.2yrs |
Recent management updates
Recent updates
Is Pliant Therapeutics (NASDAQ:PLRX) Using Too Much Debt?
Sep 13
Pliant Therapeutics: Good Data, But Will Need Watching
Sep 11Should Shareholders Reconsider Pliant Therapeutics, Inc.'s (NASDAQ:PLRX) CEO Compensation Package?
Jun 07Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?
Feb 27Is Pliant Therapeutics (NASDAQ:PLRX) Using Debt Sensibly?
Jul 21Health Check: How Prudently Does Pliant Therapeutics (NASDAQ:PLRX) Use Debt?
Mar 13Is Pliant Therapeutics (NASDAQ:PLRX) Weighed On By Its Debt Load?
Sep 10Pliant Therapeutics: Wait For A Better Price To Get In
Aug 20Pliant Therapeutics GAAP EPS of -$0.82 misses by $0.01, revenue of $4.99M
Aug 08Is Pliant Therapeutics (NASDAQ:PLRX) In A Good Position To Deliver On Growth Plans?
Jul 28Pliant's PLN-74809 gets FDA fast track status for liver disease
Jul 21Pliant climbs 48% as mid-stage trial for lung disease therapy meets key goals
Jul 11Pliant: Major Catalyst Expected Beginning Of 2023
Jun 03We're Keeping An Eye On Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Rate
Apr 22Here's Why We're Not Too Worried About Pliant Therapeutics' (NASDAQ:PLRX) Cash Burn Situation
Dec 29We Think Pliant Therapeutics (NASDAQ:PLRX) Can Afford To Drive Business Growth
Sep 07Analysts Have Just Cut Their Pliant Therapeutics, Inc. (NASDAQ:PLRX) Revenue Estimates By 12%
May 17Pliant Therapeutics, Inc. (NASDAQ:PLRX) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates
May 13Pliant Therapeutics (NASDAQ:PLRX) Is In A Good Position To Deliver On Growth Plans
Mar 22CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$202m |
| Jun 30 2024 | n/a | n/a | -US$185m |
| Mar 31 2024 | n/a | n/a | -US$171m |
| Dec 31 2023 | US$11m | US$610k | -US$161m |
| Sep 30 2023 | n/a | n/a | -US$155m |
| Jun 30 2023 | n/a | n/a | -US$144m |
| Mar 31 2023 | n/a | n/a | -US$133m |
| Dec 31 2022 | US$11m | US$587k | -US$123m |
| Sep 30 2022 | n/a | n/a | -US$113m |
| Jun 30 2022 | n/a | n/a | -US$109m |
| Mar 31 2022 | n/a | n/a | -US$103m |
| Dec 31 2021 | US$5m | US$556k | -US$97m |
| Sep 30 2021 | n/a | n/a | -US$92m |
| Jun 30 2021 | n/a | n/a | -US$81m |
| Mar 31 2021 | n/a | n/a | -US$75m |
| Dec 31 2020 | US$2m | US$499k | -US$42m |
| Sep 30 2020 | n/a | n/a | US$18m |
| Jun 30 2020 | n/a | n/a | US$19m |
| Mar 31 2020 | n/a | n/a | US$20m |
| Dec 31 2019 | US$2m | US$428k | -US$7m |
Compensation vs Market: Bernard's total compensation ($USD11.17M) is above average for companies of similar size in the US market ($USD3.21M).
Compensation vs Earnings: Bernard's compensation has increased whilst the company is unprofitable.
CEO
Bernard Coulie (58 yo)
8.8yrs
Tenure
US$11,165,999
Compensation
Dr. Bernard Coulie, Ph D, M.D. M.B.A. is Independent Director of Septerna, Inc. from December 2023. He serves as Independent Director at SQZ Biotechnologies Company since July 2021 and serves as its Indepe...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | no data | US$11.17m | 1.1% $ 9.0m | |
| Chief Financial Officer | 6yrs | US$4.44m | 0.31% $ 2.6m | |
| General Counsel & Corporate Secretary | 4.2yrs | US$3.32m | 0.060% $ 495.5k | |
| Chief Business Officer | 8.8yrs | US$4.36m | 0.32% $ 2.6m | |
| Chief Medical Officer | 6.6yrs | US$4.69m | 0.22% $ 1.8m | |
| Scientific Founder & Member of Scientific Advisory Board | 9.9yrs | no data | no data | |
| Scientific Founder & Member of Scientific Advisory Board | 9.9yrs | no data | no data | |
| Scientific Founder & Member of Scientific Advisory Board | 9.9yrs | no data | no data | |
| Scientific Founder & Member of Scientific Advisory Board | 9.9yrs | no data | no data | |
| Interim Chief Technology Officer | no data | no data | no data | |
| Vice President of Investor Relations & Corporate Communications | no data | no data | no data | |
| Chief Human Resources Officer | 1.9yrs | no data | 0.0013% $ 10.8k |
8.8yrs
Average Tenure
51yo
Average Age
Experienced Management: PLRX's management team is seasoned and experienced (8.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 8.8yrs | US$11.17m | 1.1% $ 9.0m | |
| Scientific Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Scientific Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Scientific Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Scientific Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5yrs | US$278.71k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 8.4yrs | US$277.21k | 0.058% $ 475.7k | |
| Independent Director | 7.3yrs | US$271.96k | 0.048% $ 397.0k | |
| Independent Chairman | 7yrs | US$296.71k | 0.16% $ 1.4m | |
| Independent Director | 5.8yrs | US$277.96k | 0% $ 0 | |
| Member of Scientific Advisory Board | no data | no data | no data |
7.2yrs
Average Tenure
61yo
Average Age
Experienced Board: PLRX's board of directors are considered experienced (7.2 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 05:34 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Pliant Therapeutics, Inc. is covered by 17 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Nash | Canaccord Genuity |
| Pete Stavropoulos | Cantor Fitzgerald & Co. |
| David Lebowitz | Citigroup Inc |